SPAG9 and breast carcinoma: SPAG9 has been proposed as a biomarker for diagnosis in carcinoma of the breast (41), endometrium (42), cervix (43), thyroid (44), and colon (45), and has been proposed to be involved in the tumorogenesis and growth.